You can buy or sell Ra Medical and other stocks, options, ETFs, and crypto commission-free!
Ra Medical Systems, Inc. engages in the design, development, and commercialization of excimer lasers for the treatment of dermatologic and cardiovascular diseases. Its product, Pharos, is used for the treatment of difficult-to-treat, chronic diseases including psoriasis and vitiligo. Read More It operates through the Dermatology and Vascular business segments. The company was founded by Dean Irwin and Melissa Burstein in 2002 and is headquartered in Carlsbad, CA.
52 Week High
52 Week Low
Seeking AlphaMar 15
Ra Medical down 28% on soft Q1 guidance
Thinly traded nano cap Ra Medical Systems (RMED -27.7% ) is down on modestly higher volume following its Q4 report released after the close yesterday.
Seeking AlphaMar 15
Ra Medical Systems, Inc. (RMED) CEO Dean Irwin on Q4 2018 Results - Earnings Call Transcript
Ra Medical Systems, Inc. (NYSE:RMED) Q4 2018 Earnings Conference Call March 14, 2019 4:30 PM ET Company Participants Kevin McCabe - LHA Investor Relations Dean Irwin - Chief Executive Officer, Chief Technology Officer and Chairman of the Board of Directors Thomas Fogarty - Chief Commercial Officer Andrew Jackson - Chief Financial Officer Conference Call Participants Andrew Stafford - Piper Jaffray Bruce Nudell - SunTrust Robinson Humphrey, Inc. Anthony Vendetti - Maxim Group, LLC Operator Ladies ...
Ra Medical Systems Reports 2018 Fourth Quarter and Full Year Financial Results
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, today reported financial results for the three and 12 months ended December 31, 2018 and provided a business update. Recent Operational Highlights Signed 19 new DABRA usage agreements during the fourth quarter of 2018, increasing the total number of agreements to 53 as of December 31, 2018, with varying volumes o...
-$0.38 per share
-$1.18 per share